Par Drugs (PAR) | Stock Overview & Key Data

Frequently Asked Questions

What is PAR's 52-week high and low?

In the last 52 weeks, Par Drugs reached a high of ₹348.45 (on December 2, 2024) and a low of ₹81.01 (on April 1, 2025).

What is the market cap and P/E ratio for PAR?

Curious about Par Drugs's size and valuation? Its market capitalization stands at N/A. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is N/A.

Does PAR pay dividends? If so, what's the yield?

As for dividends, Par Drugs isn't currently offering a significant yield, or that specific data isn't available right now. Its payout ratio, which shows how much of its earnings are paid as dividends, is N/A.

Who are Par Drugs's main competitors or similar companies to consider before investing?

When looking at Par Drugs, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

No specific competitor data is currently available for comparison in this section.

What are the key financial health indicators for Par Drugs and Chemicals Ltd.? (e.g., ROE, Debt/Equity)

To get a sense of Par Drugs's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is N/A, the Debt to Equity ratio from the most recent quarter is N/A, and its Gross Profit Margin stands at N/A.

What is the recent revenue and earnings growth for PAR?

Looking at Par Drugs's growth, its revenue over the trailing twelve months (TTM) was N/A. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.

How much of PAR stock is held by insiders and institutions?

Wondering who owns Par Drugs stock? Company insiders (like executives and directors) hold about N/A of the shares, while institutional investors (such as mutual funds and pension funds) own approximately N/A.

For more common questions about our data, please visit our About Data page.